One Source, Endless Solutions — A New Paradigm in Microbiome-Based Radiosensitization & Immuno-Oncology Combination Therapy
Immune checkpoint inhibitor (IO) monotherapy shows limited response rates in major solid tumors such as colorectal cancer and NSCLC. Overcoming resistance through tumor microenvironment (TME) modulation remains the central scientific challenge.
MicroMediome bridges this gap with a microbiome-based radiosensitizer, providing novel treatment options for refractory and treatment-resistant cancer patients.
Amplifies radiation effects by increasing ROS and inhibiting Bcl-2, accelerating apoptosis. Currently in development as a novel oncology drug pipeline.
Mitigates radiation side effects to protect normal tissue. Commercialized as pharmaceuticals and healthcare products to generate early-stage revenue.
Radiosensitizer & TME modulation — Accelerating apoptosis via ROS enhancement and Bcl-2 inhibition using colon-specific bacteria
● Pre-clinical / TIPSConfirmed anti-metastatic efficacy — Foci count reduced by 75% (Control 20 → MP Group 5)
● ExpansionFocused on high-prevalence cancers in Korea & Asia — Microbiome strategy to overcome PD-L1 inhibitor resistance
● ExpansionThree independent pathways of the microbiome-based anticancer platform converge to maximize tumor killing and overcome resistance
Radiosensitization through bcl-2 inhibition and ROS amplification. Accelerates the radiation-induced apoptosis cascade to maximize tumor cell killing efficiency.
Pathway 01 · RTEnhanced chemotherapy sensitivity via the Gut–Tumor Axis. Optimizes drug metabolism through gut microbiome modulation and overcomes MDR (multi-drug resistance).
Pathway 02 · ChemoAmplifies ICI response through PD-L1 downregulation and TME remodeling. Activates CD8⁺ T cells and NK cells to maximize anti-tumor immunity.
Pathway 03 · ICIFDA Approval Stage
Preparing for OTC standard
Export proceedings underway
Indoor airborne microbial data collection
Biological Big Data + Machine Learning
Disease prediction and management for atopy, asthma, and related conditions
National R&D project funded by the Ministry of Environment — Developing microbiome-based indoor air disease prediction digital healthcare services for vulnerable populations
Human Microbiome Market — High-Growth Outlook CAGR 2025–2030
| MicroMediome | Seres / Ferring | Vedanta | |
|---|---|---|---|
| Focus Area | Oncology + One Health (Broad) | Infection / CDI (Limited) | IO Checkpoint Inhibitors |
| Mechanism | Unique Radiotherapy Synergy | Microbiome Restoration | Immune Activation |
| Business Model | Dual-track (Drug + Cash Cow) | Drug Only | Drug Only |
| Status | World's First Dual-Sided Platform | Single Focus | Single Focus |
Professor of Radiation Oncology at Korea University Anam Hospital. Leads the scientific and technical direction of MBLP's radiosensitization pipeline, bridging clinical radiation oncology expertise with microbiome-based combination therapy development.
Digital healthcare for vulnerable populations — securing the right to health and improving medical accessibility
Indoor air quality improvement and prevention of environmentally-triggered diseases — microbiome-based environmental monitoring
First-in-Class microbiome combination therapy — a new therapeutic paradigm in oncology